BALANCE Study for Patients with Familial Chylomicronemia Syndrome (H-48145)

The purpose of this study is to evaluate the efficacy of an investigational drug on triglyceride level in patients with familial chylomicronemia syndrome. Participants will be randomized to receive subcutaneous injections of drug or placebo every four weeks for approximately one year. Eligibility requirements include diagnosed familial chylomicronemia syndrome, fasting triglycerides 880 mg/dL or higher, and pancreatitis within the past 10 years but not during the past four weeks.